In a first, Lilly's ready-to-use rescue hypoglycemia powder wins US approval

Days after Lilly’s chief of biomedicines Christi Shaw bid farewell to head up Novartis’ $NVS Kite business, the US drugmaker unveiled a fresh approval: a severe hypoglycemia treatment — the first such therapy given the nod in the United States that can be administered without an injection.